APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03655613 |
|
Recruitment Status :
Terminated
(Study terminated due to administrative reasons.)
First Posted : August 31, 2018
Last Update Posted : May 6, 2022
|
Sponsor:
Apollomics (Australia) Pty. Ltd.
Collaborators:
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Apollomics (Australia) Pty. Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | December 15, 2021 |
| Actual Study Completion Date : | December 15, 2021 |